>
News>
2025>
August>
NGPOD Secures an EU MDR Certification to Support Continued Growth Across Europe and the UK
NGPOD Secures an EU MDR Certification to Support Continued Growth Across Europe and the UK
In July 2025, following successful audits, NGPOD Global received certification confirming that its NGPOD Sensor (Class Is) meets the requirements of the EU Medical Device Regulation (MDR 2017/745). The NGPOD ‘POD’ (Class I) is self-certified and meets the requirements of the EU MDR 2017/745. This approval allows the organisation to continue applying the CE mark, ensuring ongoing sales across Europe and Northern Ireland.
To support its European operations, NGPOD Global is registered with its EU Authorised Representative, Advena Limited. In addition, the organisation is certified to the UK MDR 2002 (as amended), allowing the UKCA mark to be applied for sales in Great Britain.
Together, these certifications confirm NGPOD Global’s commitment to compliance and enable the continued supply of its products to healthcare providers across the UK and Europe.
More from the newsfeed
September 21, 2025
NGPOD Being Used in 20 Hospitals across United KingdomSeptember 14, 2025
NGPOD Selected for Health Innovation Network Momentum AcceleratorSeptember 7, 2025
NGPod Global at BAPEN 2025: Join us at ICC WalesSeptember 1, 2025
NGPOD to Showcase Next-Generation Digital pH Testing at HETT 2025June 25, 2025
NNNG and Welsh Stroke ConferenceWHAT IS NGPOD?
NGPod: Stop "Never Events", improve patient recovery and reduce costs
The NGPod handheld devices overcomes many of the risks associated with existing Nasogastric placement confirmation methods.
- No aspiration required
- No interpretation required. Get a clear "Yes/No" answer
- Rapid result [c.15 seconds]
- Reduce delays to patients treatment, hydration and nutrition
- More cost-effective than testing with pH strips
.jpg)
%20(1).jpg)
